Navigation Links
Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin
Date:3/16/2012

PHILADELPHIA, March 16, 2012 /PRNewswire/ -- Tarsa Therapeutics, Inc. today announced completion of a $28 million Series B equity financing led by new investor Foresite Capital.  James Tananbaum, MD, Foresite's founder and CEO, is joining Tarsa's Board of Directors.  Tarsa's existing venture capital investors—Novo A/S, MVM Life Science Partners and Quaker Partners—all participated in the new financing round. 

Following positive Phase III results and a successful pre-NDA meeting with the FDA, Tarsa is preparing to file a New Drug Application (NDA) with the US Food and Drug Administration (FDA) later this year for OSTORA™, its oral calcitonin tablet for the treatment of postmenopausal osteoporosis.  As the first once-daily oral calcitonin tablet expected to reach the market, OSTORA has the potential to offer patients and physicians the proven safety and efficacy of calcitonin with the advantage of significantly easier administration.  Proceeds from the Series B financing will support the NDA filing, preparation of a European Marketing Authorization Application (MAA) and essential pre-commercialization activities.

David Brand, President and CEO of Tarsa, said, "We are delighted to welcome experienced biotech entrepreneur and investor Jim Tananbaum as a Tarsa investor and board member, and we appreciate the continuing confidence of our existing investors who have supported Tarsa from the beginning.  This is an exciting time for the company as we prepare to file an NDA for OSTORA, and we are encouraged by the continuing strong interest in OSTORA from potential marketing partners."

"Tarsa is an excellent fit with Foresite's focus on late-stage healthcare companies developing significant medical advances," said Dr. Tananbaum.  "We believe there is substantial unmet need for additional safe and effective options for the treatment and prevention of osteoporosis, and we welcome the opportunity
'/>"/>

SOURCE Tarsa Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Tarsa Therapeutics Targets 2012 NDA Submission for its OSTORA™ Oral Calcitonin
2. Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
3. Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March
4. Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
5. Incline Therapeutics to Present at the Cowen and Company 32nd Annual Health Care Conference
6. Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial
7. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
8. Orexigen Therapeutics to Present at Upcoming Conferences
9. ResearchMoz: Nanotech Enabled Drug Delivery Therapeutics Market Will be $136 Billion by the Year 2021: Nanotechnology in Drug Delivery: Global Markets
10. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
11. Healthpoint Biotherapeutics to Present at 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... VALLEY, Calif. , July 31, 2014 ... San Francisco Bay Area , has acquired ... University of Oxford,s commercialisation company. The potent anti-inflammatory activity ... Greaves at the University of Oxford,s Sir ... The company, which has raised over $1.5 million in ...
(Date:7/31/2014)... DUBLIN , July 31, 2014 ... the "Global Genomics Market 2014-2018" report to ... Genomics is the study of the genetic ... to be a strong basis for the discovery and ... of human diseases or health conditions. Genomics is supported ...
(Date:7/31/2014)... SHENZHEN, China , July 31, 2014 ... purchase of an Irys™System by BGI ... platform to enable comprehensive exploration of human structural variation ... organisms of interest, including those where no reference exists. ... develop new methods for multiplexing on the Irys System, ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Although ... of the first transcriptome-wide analyses appearing around 2008, ... assay for RNA measurement. In the last several ... more specific, work with smaller input amounts, process ... (eg, blood samples). On the bioinformatics side, there ...
Breaking Biology Technology:Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2BioNano Genomics Announces the Purchase of the Irys System by BGI 2BioNano Genomics Announces the Purchase of the Irys System by BGI 3BioNano Genomics Announces the Purchase of the Irys System by BGI 4The Evolution of RNA-Sequencing, Upcoming Live Webinar August 22 hosted by Xtalks 2
... Corporation (Portola Valley, CA) filed in Federal District ... TMO ), alleging infringement of Spectros, spectroscopy ... invented and commercialized solid-state, broadband, integrated spectroscopy light ... into its flagship T-Stat product, replacing hot light ...
... term loanST. LOUIS, May 6 2009 First Quarter Highlights , , ... decreased to $339 million from $517 million in the first quarter of 2008 ... million from $95 million in the first quarter of 2008 , ... margins , The Company,s cash generation ...
... May 6 SpectraScience, Inc. (OTC Bulletin ... company, today announced that The Wall Street ... Chief Executive Officer Jim Hitchin. The interview, ... company,s website at http://www.spectrascience.com/tinymce/jscripts/tiny_mce/plugins/ajaxfilemanager/uploaded/Wall%20Street%20Transcript.pdf Mr. ...
Cached Biology Technology:Spectros Corporation Protects Its Cool White LED Spectroscopy Technology Against Alleged Infringement by Thermo Fisher Scientific 2Solutia Reports First Quarter 2009 Results 2Solutia Reports First Quarter 2009 Results 3Solutia Reports First Quarter 2009 Results 4Solutia Reports First Quarter 2009 Results 5Solutia Reports First Quarter 2009 Results 6Solutia Reports First Quarter 2009 Results 7Solutia Reports First Quarter 2009 Results 8Solutia Reports First Quarter 2009 Results 9Solutia Reports First Quarter 2009 Results 10Solutia Reports First Quarter 2009 Results 11Solutia Reports First Quarter 2009 Results 12Solutia Reports First Quarter 2009 Results 13Solutia Reports First Quarter 2009 Results 14Solutia Reports First Quarter 2009 Results 15Solutia Reports First Quarter 2009 Results 16Solutia Reports First Quarter 2009 Results 17Solutia Reports First Quarter 2009 Results 18Solutia Reports First Quarter 2009 Results 19Solutia Reports First Quarter 2009 Results 20Solutia Reports First Quarter 2009 Results 21SpectraScience CEO Jim Hitchin Featured in Interview With The Wall Street Transcript 2SpectraScience CEO Jim Hitchin Featured in Interview With The Wall Street Transcript 3
(Date:7/31/2014)... A Florida State University researcher found that bacteria in ... components of the oil released during the Deepwater Horizon ... the most toxic contaminants. , In two new studies ... Mason found a species of bacteria called Colwellia ... ethylbenzene and xylene compounds that were released as part ...
(Date:7/31/2014)... Biometrics industry sees growth as ... companies turn towards digital currency: NXT-ID, Inc. (OTCBB: NXTD), ... (NASDAQ: AMZN ), Facebook Inc. (NASDAQ: ... ) and Microsoft Corporation (NASDAQ: MSFT) NXT-ID, Inc., ... m-commerce market, announces a video featuring its next generation ...
(Date:7/31/2014)... While previous studies have shown that marine noise can ... scientists from the Universities of Bristol and Exeter and ... France have demonstrated that boat noise stops embryonic development ... hares, (specifically the sea slug Stylocheilus striatus ... to swim away and later feed on toxic alga ...
Breaking Biology News(10 mins):Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 2Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 3Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 4Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 5Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 6Boat noise impacts development and survival of sea hares 2
... Cancer Prognosis Two articles in the June ... demonstrate the role of stromal caveolin-1 expression as ... articles are highlighted by an accompanying Commentary. Caveolin-1, ... plays a major role in breast cancer tumorigenesis. ...
... skin appears to protect against certain types of ear ... Children,s Hospital in Columbus, Ohio, report their findings today ... for Microbiology in Philadelphia. "Our data are the ... way to prevent experimental ear infections and lays the ...
... led by David Worthylake, PhD, Assistant Professor of Biochemistry and ... help lay the groundwork for the development of a compound ... published in the May 29, 2009 issue of the ... a localized tumor to metastatic disease, cancer cells acquire the ...
Cached Biology News:Tips from the American Journal of Pathology 2Tips from the American Journal of Pathology 3Tips from the American Journal of Pathology 4Tips from the American Journal of Pathology 5Preventing ear infections in the future: Delivering vaccine through the skin 2LSUHSC research describes function of key protein in cancer spread 2